Logitech International SA vs Merck & Co., Inc. — how do they compare? Logitech International SA trades at $104.25 (market cap $14.65B), while Merck & Co., Inc. trades at $125.95 (market cap $307.25B). The key difference: Merck & Co., Inc. is far larger — about 21× Logitech International SA's market cap, and Merck & Co., Inc. pays the higher dividend (2.73%). Which is the better fit depends on your goals.
| LOGI | MRK | |
|---|---|---|
Market Cap | $14.65B | $307.25B |
Sector | Technology | Health |
52-Week High | $126.69 | $129.52 |
52-Week Low | $85.84 | $77.60 |
Enterprise Value | $13.00B | $350.66B |
Dividend Yield | 1.67% | 2.73% |
Signals from Pluang's Aura AI — not financial advice
Logitech (LOGI) trades at $101.83, down 0.98% on the day, with a bullish technical outlook supported by moving averages and strong fundamentals including a 14.69% net margin and consistent earnings beats. Recent product launches like the G3 Series and Spotlight 2 presenter highlight innovation, while a partnership with Call of Duty: Modern Warfare 4 boosts gaming segment prospects. Cash flow trends show operational strength with 2025 operating cash flow at $842.56M.
The stock offers upside to the $113 consensus price target, driven by B2B and AI product expansion, but faces risks from competitive pressures and reliance on consumer spending. Analyst sentiment is mixed with 26% buy ratings, suggesting cautious optimism amid valuation metrics like a P/E of 21.43.
Merck (MRK) trades at $124.30, down 2.51% over the past day, amid a generally bullish technical setup with moving averages signaling strength. The company reported solid earnings beats in recent quarters, including Q1 2026, with revenue reaching $65.01B in 2025 and net income of $18.25B. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives. Analyst sentiment remains strongly positive, with a consensus price target of $137.30 and 68% buy ratings.
The outlook for MRK is favorable, supported by robust profitability margins, strategic acquisitions, and strong institutional interest. Key risks include integration challenges from recent M&A, patent expirations, and regulatory pressures. The stock's current valuation at a P/E of 35.04 may limit near-term upside, but long-term growth drivers in pharmaceuticals provide a solid foundation for investor confidence.
Trailing returns across standard periods
Latest headlines on both assets
Logitech International SA is a Switzerland-based provider of personal computer and mobile accessories for navigation, video communication, and collaboration, smart home, and other applications. Its product portfolio includes mice, keyboards, charging stands, tablet cases, car mounts for mobile devices, remotes, home cameras, home switches, controllers, bluetooth speakers, surround sound, webcams, and conference cameras. It operates in a single segment namely, Peripherals. The firm generates revenue from the Americas, EMEA (Europe, Middle East, Africa), and the Asia Pacific region.
Read more on LOGI →Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →